For Research Use Only. Not for Human or Veterinary Use.
Overview
AOD-9604 is a synthetic peptide based on the C-terminal fragment of human growth hormone (hGH residues 177–191) with an added N-terminal tyrosine and a stabilising disulfide bond. In preclinical research it is studied for stimulating fat breakdown (lipolysis) and reducing fat formation (lipogenesis) in adipose tissue — reportedly without the glucose or IGF-1 effects of full-length growth hormone. It is a research compound.
🧪Chemical Profile
Property
Value
CAS number
221231-10-3
Class
Modified hGH C-terminal fragment (Tyr + hGH 177–191)
AOD-9604 corresponds to the part of growth hormone associated with its fat-metabolising activity, separated from the parts that drive growth. It is studied for acting on adipocyte metabolism — promoting lipolysis and suppressing lipogenesis — reportedly without meaningfully activating the growth-hormone receptor or raising IGF-1, which is the property that distinguishes it from full-length hGH.
Component
Detail
Lipolysis
Studied for activating hormone-sensitive lipase via cAMP/PKA
Lipogenesis
Associated with downregulation of ACC and fatty-acid synthase
cAMP
Increased intracellular cAMP in adipocytes
GH receptor
Minimal direct activation (no growth-promoting signal)
IGF-1
Does not stimulate hepatic IGF-1 production
Glucose
No effect on blood glucose in reported models
System
Studied effect
Adipose tissue
Increased lipolysis, reduced fat accumulation
Cartilage
Enhanced proteoglycan synthesis in chondrocytes
Systemic metabolism
No effect on glucose or IGF-1 (selective peripheral action)
💊Pharmacology
Parameter
Value
Half-life (t½)
≈ 2–4 h
Bioavailability (SC)
≈ 60–80% (estimated)
Tmax
≈ 30–60 min (SC)
Protein binding
Moderate
Metabolism
Proteolytic degradation
Route of administration
Subcutaneous (research)
Elimination
Renal (peptide fragments)
📚Research Evidence
AOD-9604 has adipocyte and rodent research plus some early clinical work in obesity. Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.
Model
Research focus
Reference
Human adipocytes (in vitro)
Lipolysis without GH-receptor activation
Ng FM, et al.
Rodent adipocyte culture
Glycerol release (lipolysis)
Heffernan M, et al.
Diet-induced obese mice
Body-fat reduction
AOD-9604 preclinical literature
Chondrocyte culture
Proteoglycan synthesis
AOD-9604 preclinical literature
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
Reported direction / finding
Context
Reference
Stimulated lipolysis without GH-receptor activation
human adipocytes
Ng FM et al.
Reduced body fat without glucose or IGF-1 effects
diet-induced obese mice
preclinical literature
Enhanced chondrocyte proteoglycan synthesis
cartilage cultures
preclinical literature
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
⚗️Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
Parameter
Reference value
Research dose range (literature)
≈ 300–1000 µg daily (SC), in study protocols
Reconstitution solvent
Bacteriostatic water (0.9% benzyl alcohol)
Final concentration
≈ 2.5–5 mg/mL
Storage (lyophilized)
−20°C, protected from light
Storage (reconstituted)
2–8°C, up to ~7 days
Do not use
If the solution is cloudy or contains particulates
🛡️Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
Category
Published observations
Local tolerability
Mild injection-site reactions
GI
Well tolerated in reported studies
Glucose / IGF-1
No reported effect on blood glucose or IGF-1
Cytotoxicity
No cytotoxicity observed
Status
For research use only; not for human or veterinary application
📐Physicochemical Properties
Property
Value
Physical state
White to off-white lyophilized powder
Solubility (water)
Freely soluble (> 20 mg/mL)
logP (octanol/water)
≈ −1.8 (hydrophilic)
Structural feature
One intramolecular disulfide bond (two cysteines)
pH (reconstituted)
5.0–6.5
Stability (lyophilized)
≥ 24 months at −20°C
🏭Synthesis & Manufacturing
AOD-9604 is made by Fmoc solid-phase synthesis, followed by controlled oxidative folding to form the single disulfide bond between its two cysteines — the folding step is what needs the most control to give a single defined product.
Step
Detail
Strategy
Fmoc solid-phase peptide synthesis
Resin
Wang or Rink resin
Coupling
HBTU / HOBt with DIPEA
Cleavage
TFA / TIPS / H₂O with thiol scavengers
Disulfide formation
Controlled oxidative folding (Cys7–Cys14)
Purification
Preparative RP-HPLC (C18, TFA/ACN gradient)
Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
Critical quality attributes: correct molecular weight and low deletion-peptide content. Confirm the intramolecular disulfide bond (no free thiol by Ellman’s test / MS).
🔎Analytical Methods
Method
Parameter
Typical result
RP-HPLC (C18, UV 214 nm)
Purity
≥ 98%
HPLC retention
C18, reversed-phase TFA/ACN gradient
Single main peak
ESI-MS (positive mode)
Identity / mass
consistent with the disulfide-bonded peptide
MALDI-TOF
Mass confirmation
consistent with the disulfide-bonded peptide
Amino-acid analysis
Composition
Consistent with the stated sequence
LC-MS (extracted ion)
Deletion-peptide impurities
Within specification
Karl Fischer
Water content
< 6%
LAL assay
Endotoxin
Within specification
Ion chromatography
Residual TFA
< 500 ppm
Representative RP-HPLC purity method:
Column: C18, 5 µm, 250 × 4.6 mm
Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
Confirmatory LC-MS: ESI positive mode (consistent with the disulfide-bonded peptide). Confirm the intramolecular disulfide bond (no free thiol by Ellman’s test / MS).
📈Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
Condition
Duration
Result
Lyophilized, −20°C, dark
≥ 24 months
No significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark
≥ 12 months
Minimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)
3 months
< 5% degradation
Reconstituted, 2–8°C, dark
7–14 days
Minor degradation
Reconstituted, 25°C
24–48 h
Use promptly
Light exposure (ICH Q1B)
1.2 M lux·h
Generally light-stable
Freeze–thaw (−20°C ⇄ 25°C)
3 cycles
Acceptable — aliquot to avoid repeats
Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
Minimise freeze-thaw cycles; aliquot material used across many sessions.
Key factor: Confirm the intramolecular disulfide bond (no free thiol by Ellman’s test / MS).
📖Selected References
Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD-9604) of human growth hormone. Molecular and Cellular Endocrinology.
Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology / Life Sciences.
AOD-9604 preclinical and early-clinical obesity literature.
✅Quality & Supply
HPLC ≥ 98% purity with a Certificate of Analysis per batch
Identity confirmed by LC-MS; disulfide confirmed
Research samples through to bulk, with worldwide delivery